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Purpose: Laxative-refractory opioid-induced con-
stipation (OIC) is deﬁned as OIC despite using 2
laxatives with a different mechanism of action (based
on the Anatomical Therapeutic Chemical Classiﬁca-
tion System level 4 term [contact laxatives, osmoti-
cally acting laxatives, softeners/emollients, enemas,
and others]). OIC has a signiﬁcant impact on the
treatment and quality of life of patients with severe
chronic pain. This noninterventional, observational,
real-life study in Belgium investigated the efﬁcacy of
prolonged-release oxycodone/naloxone combination
(PR OXN) treatment regarding pain relief and OIC
compared with previous prolonged-release oxycodone
(PR OXY) treatment for laxative-refractory OIC in
daily clinical practice.
Methods: Laxative-refractory OIC patients with
severe chronic pain were treated with PR OXN for
12 weeks (3 visits). Pain relief (assessed on a numerical
rating scale) and OIC (assessed by using the Bowel
Function Index [BFI]) were evaluated at each visit. A
responder was deﬁned as a patient who had: (1) no
worsening of pain at the last visit compared with visit
1 or a numerical rating scale r4 at visit 3/last visit;
and (2) a reduction in BFI Z12 units at visit 3/last
visit compared with visit 1; or (3) a BFIr28.8 at visit
3/last visit.
Findings: Sixty-eight laxative-refractory OIC
patients with severe chronic pain (mean (sd) age
59.8 (13.3) years, 67.6% female and 91.2% non-
malignant pain) were treated for 91 days with PR784OXN (median daily dose, 20 mg). Treatment with PR
OXN resulted in a signiﬁcant and clinically relevant
decrease of pain of 2.1 units (P o 0.001; 95% CI,
1.66–2.54) and of BFI by 48.5 units (Po 0.001; 95%
CI, 44.4–52.7) compared with PR OXY treatment;
use of laxatives was also signiﬁcantly reduced (P o
0.001). Approximately 95% of patients were respond-
ers, and quality of life (as measured by using the EQ-
5D) improved signiﬁcantly. Adverse events were
opioid related, and PR OXN treatment was well
tolerated.
Implications: Treatment with PR OXN resulted in a
signiﬁcant and clinically relevant reduction in OIC
compared with previous PR OXY treatment for these
patients with severe chronic pain and laxative-
refractory OIC. Treatment with PR OXN also resulted
in a signiﬁcant improvement in pain relief and quality
of life. ClinicalTrials.gov identiﬁer: NCT01710917.
(Clin Ther. 2015;37:784–792) & 2015 The Authors.
Published by Elsevier HS Journals, Inc.
Key words: laxative refractory, laxatives, opioid-
induced constipation, pain, quality of life.Volume 37 Number 4
J. Poelaert et al.INTRODUCTION
Opioids are widely used for the treatment of patients
with severe chronic pain. However, adverse drug reac-
tions associated with the use of opioids, particularly
opioid-induced bowel dysfunction, can be problematic
and severely affect quality of life.1 Opioid-induced
constipation (OIC) is the most distressing symptom of
opioid-induced bowel dysfunction and occurs in 40%
of opioid-treated patients.2,3 In contrast to opioid-
related adverse effects mediated through the central
opioid receptors, which occur at the start of treatment
and usually rapidly lessen, OIC is mediated through
intestinal opioid receptors and often persists throughout
opioid treatment with no decline in intensity.4 OIC is the
most troublesome opioid-related adverse effect reported
by patients, resulting in reduction or discontinuation of
treatment in one third of opioid-treated patients.1
Laxatives are the most common drugs used for
relieving OIC. However, because laxatives do not
address the underlying mechanisms of OIC, they are
insufﬁciently effective in the majority of patients
experiencing this condition.5,6 Moreover, there are no
direct comparative data on different laxatives in the
prevention or treatment of OIC, resulting in a lack of
generally accepted guidelines regarding laxative use for
this condition.6
One strategy to minimize or prevent OIC while
maintaining analgesic efﬁcacy is blocking intestinal
opioid receptors while allowing the activation of
central opioid receptors.6 To this end, a prolonged-
release tablet consisting of oxycodone and naloxone
(PR OXN) in a 2:1 ratio was developed. Oxycodone
has been shown to be an effective analgesic in various
types of pain.7 Naloxone is an opioid receptor
antagonist with low systemic bioavailability (o3%)
primarily used as an injectable solution for the
treatment of opioid overdose by its antagonizing
effect on central opioid receptors. When administered
orally, naloxone antagonizes the opioid receptors in
the gut wall, thereby counteracting OIC, while its
extensive ﬁrst-pass hepatic metabolism ensures the lack
of antagonist inﬂuence on the central analgesic effect of
oxycodone.8
Several randomized controlled studies have reported
on the comparable analgesic efﬁcacy of PR OXN and
prolonged-release oxycodone (PR OXY), with a sig-
niﬁcant and clinically relevant improvement in OIC
with PR OXN compared with PR OXY in various
types of pain even after long-term treatment.9–15 TheApril 2015frequency of adverse events was similar between PR
OXN and PR OXY treatments. This outcome was
conﬁrmed in daily clinical practice in Germany for
patients with a variety of pain etiologies.16
PR OXN is indicated for the treatment of severe
pain that can only be adequately managed with opioid
analgesics. In Belgium, reimbursement for PR OXN is
strictly limited to patients who have been treated with
PR OXY for at least the last 30 days before PR OXN
treatment and who are experiencing laxative-
refractory OIC; this form is deﬁned as OIC despite
the use of at least 2 laxatives with different mecha-
nisms of action (based on the Anatomical Therapeutic
Chemical [ATC] Classiﬁcation System level 4 term [eg,
contact laxatives, osmotically acting laxatives, soften-
ers/emollients, enemas, and others) during previous
PR OXY treatment.
The present real-life study was requested by the
Belgian reimbursement authorities to investigate the
efﬁcacy of PR OXN in terms of both pain relief and
OIC in chronic pain patients eligible for PR OXN
reimbursement in Belgium. In addition to evaluation
of efﬁcacy regarding pain relief and OIC use of
laxatives and analgesic rescue medication, quality of
life and safety during PR OXN treatment compared
with the previous PR OXY treatment were evaluated.
PATIENTS AND METHODS
Study Design
This noninterventional, observational, real-life
study was designed to evaluate the pain relief and
OIC of PR OXN treatment in daily practice in
patients with chronic severe pain compared with
previous PR OXY treatment. PR OXN treatment
was started at visit 1. The study was performed by
using electronic case record forms, and all parameters
collected at visit 1 reﬂected the PR OXY treatment.
Evaluations were performed during 2 follow-up visits.
Visit 2 was scheduled after PR OXN dose titration,
and visit 3 was scheduled at least 12 weeks after
visit 1.
The study was conducted in accordance with
Belgian and European health law and controlled drug
regulations.
Patients
Patients enrolled in the present study met the
reimbursement conditions for PR OXN in Belgium
as well as the summary of product characteristics for785
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imbursement if they meet the following conditions:
(1) all patients had to be aged Z18 years, with a
documented history of severe pain requiring around-
the-clock opioid therapy, treated with PR OXY for at
least 30 days with insufﬁcient pain relief and/or
unacceptable adverse effects; and (2) all patients had
to be experiencing OIC (Bowel Function Index [BFI]
Z28.8 [discussed later in the Patients and Methods])
despite the use of at least 2 laxatives with different
mechanisms of action (level 4 ATC term) during the
previous PR OXY treatment.
Patients were excluded from the study if they met
any of the following criteria (based on the summary of
product characteristics): any history of hypersensitiv-
ity to oxycodone, naloxone, related products, or other
ingredients; active alcohol or drug abuse and/or
history of opioid abuse; participation in a clinical
research study involving a new chemical entity or an
experimental drug within 30 days of study entry;
surgery completed before the start of the study or
planned surgery during the study that would inﬂuence
pain or bowel function; or use of naloxone r30 days
before the start of the study. Patients were also
excluded if they had any of the following: diarrhea
and/or opioid withdrawal; any situation in which
opioids were contraindicated; or severe respiratory
depression with hypoxia and/or hypercapnia, severe
obstructive pulmonary disease, cor pulmonale,
severe bronchial asthma, nonopioid-induced paralytic
ileus, and moderate to severe liver function impair-
ments. Pregnant or breastfeeding women were also
excluded.
Written informed consent was obtained from all
patients for the anonymous use of the data.
Medication
PR OXN is available in oxycodone/naloxone tab-
lets of 5 mg/2.5 mg, 10 mg/5 mg, 20 mg/10 mg, and
40 mg/20 mg and was prescribed to the patients
according to the summary of product characteristics.
Patients were switched immediately from PR OXY to
PR OXN with equal oxycodone doses. After the
switch to PR OXN, the PR OXN dose could be
titrated as needed. Use of laxatives and analgesic
rescue medication as well as other comedication was
allowed during PR OXN treatment (as in daily clinical
practice) and was documented (yes/no was manda-
tory; type and dosage were optional).786Study Assessments
Primary Parameter
The primary parameter was the percentage of res-
ponders after 12 weeks of PR OXN treatment. The
response was based on the parameters of pain and OIC.
Pain was assessed at each visit by the physician
on a numerical rating scale (NRS) from 0 (no pain) to
10 (worst pain). OIC was evaluated by the physician
using the validated BFI.17,18 Copyright for the BFI is
owned by Mundipharma Laboratories GmbH, Swit-
zerland 2002; the BFI is the subject of European
Patent Application Publication No. EP 1 860 988
and corresponding patents and applications in other
countries. This index uses a numerical scale from
0 (easy/no difﬁculty) to 100 (severe difﬁculty/very
strong) to record a patient’s subjective assessment of
3 items related to OIC: ease of defecation, feeling of
incomplete bowel evacuation, and personal judgment
regarding OIC. The BFI is calculated as the arithmetic
mean of the scores for these 3 items. A lower score
indicates a better bowel function; a score of r28.8 is
considered a normal bowel function with respect to
OIC, and a BFI change of Z12 points is considered a
clinically relevant change.17–19
Responders
A patient was deﬁned as a responder if the patient
had: (1) no worsening of pain (NRS increase r1 unit
at visit 3/last visit compared with visit 1 or an NRS
r4 at visit 3/last visit; and (2) had a reduction in BFI
of Z12 units at the last visit compared with visit 1 or
a BFI r28.8 at visit 3/last visit.
Secondary Parameters
Secondary parameters included the use of laxatives
and analgesic rescue medication, evaluation of the
quality of life, and safety assessments during PR OXN
treatment compared with the previous PR OXY
treatment.
Laxative use was assessed by asking if the patient
had used laxatives in the 7 days before each study visit
(yes or no); information on whether laxative use had
increased/decreased or remained constant compared
with the previous visit was also registered (decrease/
constant/increase). If laxatives were used in the 7 days
before the study visit, information regarding type,
dose, and frequency of the used laxatives was optional
due to the noninterventional character of the study.
The percentage of patients using laxatives in theVolume 37 Number 4
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patients reporting increased/decreased/stable laxative
use at visits 2 and 3 compared with visit 1 were
calculated.
The assessment of the use of analgesic rescue medi-
cation was similar to the assessment of laxative use.
The patient’s quality of life was evaluated by using
the standardized EQ-5D questionnaire. The EQ-5D
score and EQ-5D visual analog scale (VAS) health
score were recorded at visit 1 and at the last visit.
A derived EQ-5D score was calculated from the
5 items (mobility, self-care, usual activities, pain/
discomfort, and anxiety/depression) as well as the
absolute change in EQ-5D score and EQ-5D VAS
health score between the last visit and visit 1.
Safety assessments consisted of monitoring and
recording all serious adverse events (AEs) and adverse
reactions at all visits.
Statistical Analysis
For the efﬁcacy parameters, the analyses were
performed for all patients meeting the inclusion
criteria who received at least 1 dose of PR OXN
treatment and who had at least 1 postdose efﬁcacy
evaluation (ie, the full analysis population). Patients
using laxatives during the 30-day PR OXY treatment
were included in this full analysis. Because patients
were not asked proactively about laxative treatment
before starting the study, and because the laxative use
during the last 7 days was evaluated at the consecutive
visits, a decision was made to also analyze the primary
parameter for patients who used laxatives in the
7 days instead of 30 days before study inclusion (ie,
the per-protocol population). The safety analysis was
performed for all patients who had received at least 1
dose of study medication and had at least 1 safety
assessment after the last dose (safety population).
Descriptive statistics of all demographic character-
istics, baseline variables, and study parameters were
provided overall. Continuous data were summarized
according to their mean, SDs, 95% CIs of the mean,
median, and minimum and maximum. Categorical
and ordinal data were summarized according to
frequency and percentages. No imputation of missing
data was performed.
A paired t test was used to test if there was a
change in mean pain NRS, BFI, and EQ-5D score
between the ﬁrst and last visits. The McNemar test for
paired data was used to determine if there was aApril 2015change in use of laxatives or use of analgesic rescue
medication between the ﬁrst and the last visits. The
effect of the treatment time on changes in mean BFI
scores was studied in more detail by using linear
mixed effect models. All statistical tests were per-
formed by using a 2-sided signiﬁcance level of 5%.
RESULTS
A total of 68 patients were included in the full analysis
population (Figure 1). Approximately 91% of the
patients (62 of 68) completed the study. Three
patients (4.4%) discontinued of their own choice:
1 patient stopped due to an AE, and 2 patients
(2.9%) discontinued for other reasons. For 3 subjects,
no laxative intake for the last 7 days was documented,
and 65 patients were thus included in the per-protocol
analysis.
Table I displays the data for age, sex, and pain
diagnoses for enrolled patients. The median study
duration was 91 days (range, 7–127 days), with
37.5 days (range, 3–85 days) for visit 2 (dose
titration) and 91 days for visit 3 (range, 39–127
days). These variations in durations were due to the
noninterventional design of the study. The median
dose of PR OXY treatment used before the start
of the study (visit 1) was 20 mg (range, 5–360 mg).
The median prescribed dose of PR OXN at visit 1 was
similar to that of PR OXY (20 mg [range, 10–360
mg]). At visits 2 and 3, the median dose of PR OXN
remained stable at 20 mg (range, 10–360 mg).
Efficacy of PR OXN Treatment with Regard to
Pain Relief
The pain NRS was signiﬁcantly reduced (P o
0.001) on average 2.1 units (95% CI, 1.66–2.54)
between visit 1 (mean, 6.8 [1.5]) and visit 3 (mean, 4.6
[1.5]) (Figure 2). The mean pain NRS was also
signiﬁcantly decreased over time during PR OXN
treatment to 3.8 after 18 weeks.
Efficacy of PR OXN Treatment with Regard to
OIC
The BFI was signiﬁcantly reduced (P o 0.001) on
average 48.5 units (95% CI, 44.4 to 52.7) between
visit 1 (mean, 70.8 [16.2]) and visit 3 (mean, 21.3
[13.2]) (Figure 3). The BFI signiﬁcantly improved
(P o 0.001) on average 3.4 units (95% CI, –3.8 to
–3.0) per week during PR OXN treatment. This
improvement on the BFI was clinically relevant, with787
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Figure 1. Patient diagram. The full analysis
population included all patients meet-
ing the inclusion criteria who received
at least 1 dose of prolonged-release
oxycodone treatment during the
study and who had at least 1 post-
dose efficacy evaluation. The per-pro-
tocol population included all patients
meeting the inclusion criteria who
took laxatives in the 7 days before
study inclusion.
Table I. Baseline characteristics of the patients
(N ¼ 68, full analysis population).
Characteristic Value
Age, y, mean (SD) 59.8 (13.3)
Sex, no. (%)
Male 22 (32.4)
Female 46 (67.6)
Pain diagnosis, no. (%)
Malignant 4 (5.9)
Nonmalignant* 62 (91.2)
Osteoarthritis 19 (30.6)
Arthritis 1 (1.6)
Low back pain 26 (41.9)
Neuropathic pain 22 (35.5)
Osteoporosis 2 (3.2)
Postoperative pain 6 (9.7)
Other 9 (14.5)
Unknown 2 (2.9)
*For patients with nonmalignant pain, multiple
diagnoses were possible.
Clinical Therapeuticsan average of 13.6 units (95% CI, 12 to 15.2) after 4
weeks of PR OXN treatment. After 6 weeks of PR
OXN treatment, the average BFI waso28.8, and thus
patients were considered no longer constipated.
Efficacy of PR OXN Treatment in Terms of
Responders
The efﬁcacy of PR OXN regarding pain relief and
OIC was expressed as the percentage of responders788after 12 weeks of PR OXN treatment compared with
the previous PR OXY treatment. Data for 1 and
2 patients were missing for the full analysis and per-
protocol populations, respectively (Figure 1, primary
parameter). Among the full analysis population, 58 of
61 patients were qualiﬁed as responders (95.1% [95%
CI, 86.0–98.9]); for the per-protocol population, 55 of
58 patients (94.8% [95% CI, 85.3–98.8]) were quali-
ﬁed as responders.
Use of Laxatives
The number of patients using laxatives in the
7 days before each visit decreased signiﬁcantly from
65 patients (95.6%) at study start to 24 patients
(38.7%) at visit 3 (McNemar test χ2(1) ¼ 37.0,
P o 0.001) (Table II).
The optional ﬁeld for type of laxative was regis-
tered for 32 of 65 patients at visit 1; the majority of
these patients (73%) used polyethylene glycol; 30%,
bisacodyl; 17%, sodium picosulfate; 17%, senna; 8%,
lactulose; and 8%, rectal laxatives. The sum of these
percentages is 4100% because 41 laxative could be
registered.Volume 37 Number 4
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Figure 2. Average pain score (numerical rating
scale [NRS]) with SDs per visit (full
analysis population). Number of pa-
tients: visit 1, n ¼ 60; visit 2, n ¼ 59;
and visit 3, n ¼ 54. *Indicates a
significant reduction in pain NRS com-
pared with visit 1 (P o 0.001, linear
mixed effect model).
J. Poelaert et al.Within the group of 41 patients using laxatives at
visit 2, a total of 37 patients (90.2%) reported a
decreased use of laxatives in the last 7 days compared
with the preceding PR OXY treatment. Of the 24
patients using laxatives at visit 3, a total of 20 patients
(83.3%) reported a decreased use of laxatives in the
last 7 days compared with the preceding PR OXY
treatment.100
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Figure 3. Average bowel function index (BFI)
with SDs per visit (full analysis popu-
lation). Number of patients: visit 1,
n ¼ 67; visit 2, n ¼ 66; and visit 3,
n ¼ 61. *Indicates a significant reduc-
tion in BFI compared with visit 1 (Po
0.001, linear mixed effect model).
April 2015Use of Analgesic Rescue Medication
The number of patients using analgesic rescue
medication in the 7 days before each study visit
decreased signiﬁcantly from 44 patients (64.7%) at
study start to 26 patients (41.9%) at visit 3 (McNemar
test χ2(1) ¼ 13.1, P o 0.001). The optional ﬁeld for
type of rescue medication was registered for 28 of 44
patients, 19 of 37 patients, and 15 of 26 patients at
visits 1, 2, and 3, respectively. The majority of these
patients (visit 1, 68%; visit 2, 63%; and visit 3, 66%)
used oxycodone as rescue medication.
Quality of Life
The EQ-5D score increased signiﬁcantly (on aver-
age) 0.275 unit (95% CI, 0.202–0.347) between visit
1 (mean, 0.247 [0.233]) and the last visit (mean, 0.522
[0.275]) (P o 0.001). The EQ-5D VAS health score
increased signiﬁcantly (on average) 25.2 units (95%
CI, 20.1–30.3) between visit 1 (mean, 33.0 [13.0]) and
the last visit (mean, 58.2 [16.8]) (P o 0.001).
Safety Analysis
Only 2 patients (2.9%) reported an AE. One
patient reported euphoria and drowsiness at visit 2.
The other patient had an epileptic seizure after visit 2;
however, this episode was considered to be unrelated
to PR OXN treatment.
AEs were of average intensity and were pharmaco-
logically treated, leading to elimination of the AE. No
serious AEs were reported throughout the study.
DISCUSSION
The present study, requested by the Belgian reimburse-
ment authorities, evaluated the efﬁcacy of PR OXN in
terms of pain relief and OIC in 68 patients with chronic
pain who were treated with PR OXY during at least the
last 30 days before PR OXN treatment and who
experienced OIC despite the use of at least 2 laxatives
with different mechanisms of action (level 4 ATC term).
To the best of our knowledge, this is the only non-
interventional study of opioid treatment in which laxative
use was documented before and during the treatment.
This study found that PR OXN was superior to PR
OXY in terms of pain relief, OIC, and quality of life in
patients with chronic pain previously treated with PR
OXY and experiencing OIC despite the use of at least
2 different laxatives. The mean pain NRS was signiﬁ-
cantly reduced, on average, 2.1 units during treatment
with PR OXN, comparable to other studies previously789
Table II. Laxative use in the 7 days before the study visit. Data are given as no. (%).
Laxative Use Visit 1* Visit 2† Visit 3† Last Visit†
Yes/no 65/3 (95.6/4.4) 41/26 (60.3/ 38.2) 24/38 (38.7/61.3) 26/42 (38.2/61.8)
Decrease/constant/
increased‡
NA 37/3/1 (90.2/7.3/2.4) 20/4/0 (83.3/16.7/0) 21/5/0 (80.8/19.2/0)
Missing data 0 1 (1.5) 0 0
NA ¼ not available.
*Laxative used in the last 7 days before study inclusion. These data are considered data for laxative use during the previous
prolonged-release oxycodone (PR OXY) treatment.
†Laxative used in the last 7 days before study visit: yes/no and increased, decreased, or constant laxative use during
prolonged-release oxycodone/naloxone combination treatment compared with the preceding PR OXY treatment.
‡Decrease/constant/increased laxative use for patients who used laxatives during the preceding PR OXY treatment.
Clinical Therapeuticsdemonstrating similar analgesic efﬁcacy of PR OXN
and PR OXY even after long-term treatment with PR
OXN.4,9,12–15 The median PR OXN daily dose of
20 mg remained constant throughout the study and
was equal to the PR OXY dose during the preceding
PR OXY treatment. Moreover, the use of analgesic
rescue medication decreased signiﬁcantly during PR
OXN treatment compared with the preceding PR
OXY treatment. The observed improved pain relief
during PR OXN treatment can therefore not be
explained by an increased dose or increased use of
analgesic rescue medication and is probably related to
the improved OIC during PR OXN treatment.
This is the ﬁrst noninterventional study in which
the effect of PR OXN on OIC was evaluated by using
2 parameters: BFI and laxative use. The BFI exhibited
a statistically signiﬁcant and clinically relevant im-
provement of 48.5 points from visit 1 to the last visit.
A change in BFI of Z12 points has proven to be
related to clinically meaningful changes in bowel
habits in patients with OIC.18 This study conﬁrmed
that after 4 weeks of treatment with PR OXN, a
clinically relevant improvement in OIC was attained
in patients experiencing laxative-refractory OIC. The
average BFI was o28.8 after 6 weeks of PR OXN
treatment, indicating that most patients were no
longer constipated despite the opioid treatment.19
In addition to the BFI, PR OXN efﬁcacy regarding
OIC was investigated by comparing the use of laxatives
between the previous PR OXY treatment and PR OXN
treatment. The number of patients using laxatives
declined signiﬁcantly during PR OXN treatment com-
pared with PR OXY treatment. If laxatives were790needed, the majority of patients using laxatives during
PR OXN treatment indicated decreased laxative use
during PR OXY treatment. Therefore, the improve-
ment in OIC observed during PR OXN treatment
cannot be explained by an increased use of laxatives.
This supports the rationale that PR OXN treatment
counteracts OIC through mechanisms other than those
of laxatives and that PR OXN addresses the underlying
mechanism of OIC. The results of this noninterven-
tional study are similar to results of a pooled analysis of
laxative-refractory OIC patients from studies with PR
OXN with respect to BFI and laxative use.20 This
pooled analysis showed that PR OXN signiﬁcantly
improved bowel function and reduced the use of
laxatives in patients with OIC who were previously
unresponsive to at least 2 different classes of laxatives.
PR OXN also provided effective analgesia for pa-
tients with moderate to severe cancer-related and non–
cancer-related pain. The efﬁcacy of PR OXN regarding
pain relief and OIC was expressed as the percentage of
responders after PR OXN treatment compared with the
percentages from the previous PR OXY treatment. The
percentage of responders was 95.1% after 12 weeks of
PR OXN treatment, indicating that almost all patients
experienced a pain NRS score r4 or improved pain
relief in the absence of OIC (BFI r28.8) or with a
clinical improvement in OIC (BFI improvement Z12
units) compared with the preceding PR OXY treatment.
Quality of life improved signiﬁcantly during PR OXN
treatment. The overall EQ-5D score and EQ-5D VAS
health score increased signiﬁcantly, on average, 0.275
and 25.2 units, respectively, after 12 weeks of PR OXN
treatment compared with PR OXY treatment. ThisVolume 37 Number 4
J. Poelaert et al.improved quality of life probably reﬂects the improved
pain relief and OIC during PR OXN treatment and is
consistent with the results of previous studies.4,16,21
PR OXN treatment was well tolerated in this study,
and no serious AEs were reported. The frequency of
AEs was lower compared with other studies, which can
be explained by the observational design of the study.
Remarkably, 1 patient was directly switched from a
daily dose of 360 mg of oxycodone to an equivalent dose
of 360 mg/180 mg of oxycodone/naloxone. In current
literature, daily doses of up to 240 mg/120 mg of
oxycodone/naloxone have been described using a step-
wise switch from oxycodone to oxycodone/naloxone
with different outcomes.14,22 Close review of the patient’s
records revealed that the patient responded well to the
direct switch. Pain relief with oxycodone was comparable
to pain relief with oxycodone/naloxone (pain NRS score
was 3 throughout the 87-day treatment period). More-
over, no AEs were reported, the patient did not require
any analgesic rescue medication or other concomitant
medication, and a decrease in laxative medication was
reported in addition to an improvement in bowel function
after the switch from oxycodone to oxycodone/naloxone
(BFI decreased from 46.7 to 0).
A noninterventional study has limitations, one of
them being that we could not ensure that all data were
documented in the database. This limitation was ad-
dressed by marking important parameters (eg, BFI, pain
relief, laxative use yes/no, rescue medication yes/no) as
mandatory ﬁelds in the electronic case record form; as a
result, few data were missing for these ﬁelds.
Although keeping the inherent limitations of a
noninterventional study in mind, the effects of PR
OXN in real-life clinical practice in Belgium for those
patients who were eligible for reimbursement found
signiﬁcant reductions in OIC during treatment of PR
OXN in laxative-refractory OIC patients. The results
of this real-life study conﬁrmed the improvement seen
in a pooled analysis from pivotal studies with PR
OXN in a comparable patient group.20
CONCLUSIONS
In this real-life study in Belgium, patients with chronic
severe pain and OIC despite the use of at least
2 laxatives with different mechanisms of action (level
4 ATC term) experienced a signiﬁcant improvement in
pain relief, a signiﬁcant and clinically relevant reduc-
tion in OIC, and a signiﬁcant improvement in quality
of life after PR OXN treatment compared withApril 2015previous PR OXY treatment. The percentage of
responders was 95.1% after 12 weeks of PR OXN
treatment, indicating that almost all patients experi-
enced no pain or improved pain relief in the absence
of OIC or with a clinical improvement in OIC
compared with the preceding PR OXY treatment.
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